Arcutis Biotherapeutics vs Protagonist Therapeutics
ARQT and PTGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARQT and PTGX compare
Protagonist Therapeutics is the larger company, worth 2.4 times as much as Arcutis Biotherapeutics ($8.5B against $3.6B).
On earnings, Protagonist Therapeutics is cheaper: it trades at 27.7× trailing earnings, against 128× for Arcutis Biotherapeutics.
Protagonist Therapeutics grew revenue faster over the last twelve months (164% versus 60.0% for Arcutis Biotherapeutics).
Protagonist Therapeutics keeps more of each dollar of sales as profit, with a net margin of 62.0% compared with 5.9% at Arcutis Biotherapeutics.
Protagonist Therapeutics scores higher on the StockData Score (16 against 11 for Arcutis Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARQT | PTGX |
|---|---|---|
| Size and price | ||
| Market cap | $3.6B | $8.5B |
| Share price | $28.26 | $130.95 |
| Change, 1 year | 20.5% | 54.3% |
| Change, 5 years | 55.4% | 274% |
| Beta (5Y) | 0.92 | 0.78 |
| Employees | 354 | 132 |
| StockData Score | ||
| Total score | 11 | 16 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 4 (better) | 2 |
| Performance score | 4 | 4 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 128× | 27.7× (better) |
| P/S | 7.0× (better) | 15.4× |
| P/B | 14.6× | 7.8× (better) |
| EV/EBITDA | 96.7× | 23.6× (better) |
| P/FCF | 59.5× (better) | 77.6× |
| FCF yield | 1.7% (better) | 1.3% |
| Fair value | $6.04 | $183.25 |
| Margin of safety | −368% | 28.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 60.0% | 164% (better) |
| Revenue growth, 5Y average | – | 10.0% |
| Net income growth (TTM) | – | 646% |
| EPS growth (TTM) | – | 661% |
| Profitability | ||
| Gross margin | 91.2% | – |
| Operating margin | 6.9% | 58.6% (better) |
| Net margin | 5.9% | 62.0% (better) |
| FCF margin | 11.7% | 19.8% (better) |
| Return on equity | 14.9% | 39.6% (better) |
| Return on invested capital | 32.9% | 178% (better) |
| Financial health | ||
| Debt / equity | 0.45 (better) | 0.00 |
| Net debt / EBITDA | −4.27 | – |
| Interest coverage | 2.6× | – |
| Current ratio | 2.92 | 19.85 (better) |
| Altman Z-score | 6.54 | 84.88 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 105% | 117% |
| Held by insiders | 9.3% | 1.7% |
| Insider net buying, 12 months | −$11.1M (better) | −$95.0M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 15.9% | 16.1% |
Go deeper
- ARQT stock overview
- ARQT income statement
- ARQT valuation and score
- PTGX stock overview
- PTGX income statement
- PTGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.